Tessera Defense & Homeland Security Inc.HLSQ
Price (close)
$0.53
Market cap
$14.1M
P/E
—
Revenue (TTM)
—
Net income
-$45.5M
Dividend yield
—
1-year total return
—
Net margin
—
Revenue growth
—
Debt / equity
0.04x
What Tessera Defense & Homeland Security Inc. does.
are a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target
Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are
considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and by creating novel phage using
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$30.1M | -$36.2M | -$28.3M | -$26.2M | -$17.7M | -$36.2M |
| Free cash flow | -$25.5M | -$31.3M | -$29.2M | -$21.3M | -$37.0M | -$26.4M |
More on HLSQ.
- Tessera Defense & Homeland Security Inc. summary
- Tessera Defense & Homeland Security Inc. financial statements
- Tessera Defense & Homeland Security Inc. key metrics
- Tessera Defense & Homeland Security Inc. health scores and style box
- Tessera Defense & Homeland Security Inc. earnings
- Tessera Defense & Homeland Security Inc. dividends
- Tessera Defense & Homeland Security Inc. valuation
- Tessera Defense & Homeland Security Inc. ownership and insiders
- Tessera Defense & Homeland Security Inc. peers
Figures from Tessera Defense & Homeland Security Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.